Dossier
Alliance for Regenerative Medicine
Coverage of Alliance for Regenerative Medicine in the Nexus archive.
- STAT+: Pharmalittle: We’re reading about a PhRMA ad campaign aimed at 340B, sales of Novo’s obesity pill, and more
The Pharmaceutical Research and Manufacturers of America is launching a seven-figure ad campaign targeting the 340B Drug Pricing Program, while the US Food and Drug Administration has seen an increase in rejection rates for cell and gene therapies. The program requires manufacturers to provide drugs at reduced prices to health providers caring for low-income patients. The ad campaign aims to manipulate the program's benefits.